Current Drug Therapy
The role of SGLT-2 inhibitors in managing type 2 diabetes
Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088
Yumiko Tsushima
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic
M. Cecilia Lansang
Director, Main Campus Department of Endocrinology, Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Vinni Makin
Director, East Region, Department of Endocrinology Diabetes, and Metabolism, Cleveland Clinic; Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

REFERENCES
- ↵
- ↵
- ↵
- ↵
- Nauck MA,
- Del Prato S,
- Meier JJ,
- et al
- ↵
- Roden M,
- Weng J,
- Eilbracht J,
- et al
- ↵
- Ferrannini E,
- Ramos SJ,
- Salsali A,
- Tang W,
- List JF
- ↵
- Aronson R,
- Frias J,
- Goldman A,
- Darekar A,
- Lauring B,
- Terra SG
- ↵
- Cefalu WT,
- Leiter LA,
- Yoon KH,
- et al
- ↵
- Häring HU,
- Merker L,
- Seewaldt-Becker E,
- et al
- ↵
- ↵
- ↵
- Rosenstock J,
- Jelaska A,
- Frappin G,
- et al
- ↵
- ↵
- ↵
- Kristensen SL,
- Preiss D,
- Jhund PS,
- et al
- ↵
- Kristensen SL,
- Mogensen UM,
- Jhund PS,
- et al
- ↵
- Bertoni AG,
- Hundley WG,
- Massing MW,
- Bonds DE,
- Burke GL,
- Goff DC Jr.
- ↵
- Vaur L,
- Gueret P,
- Lievre M,
- Chabaud S,
- Passa P,
- DIABHYCAR Study Group (type 2 DIABetes, Hypertension, CARdiovascular Events and Ramipril) study
- ↵
- ↵
- ↵
- ↵
- ↵
- Zelniker TA,
- Wiviott SD,
- Raz I,
- et al
- ↵
- ↵
- Yancy CW,
- Jessup M,
- Bozkurt B,
- et al
- ↵
- ↵
- US Food and Drug Administration (FDA)
- ↵
- ↵
- Kosiborod M,
- Lam CSP,
- Kohsaka S,
- et al
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- Nespoux J,
- Vallon V
- ↵
- ↵
- Mosenzon O,
- Wiviott SD,
- Cahn A,
- et al
- ↵
- American Diabetes Association
- ↵
- ↵
- Ruggenenti P,
- Porrini EL,
- Gaspari F,
- et al
- ↵
- Heerspink HJ,
- Perkins BA,
- Fitchett DH,
- Husain M,
- Cherney DZ
- ↵
- ↵
- Hollander P,
- Bays HE,
- Rosenstock J,
- et al
- ↵
- ↵
- ↵
- ↵
- Bolinder J,
- Ljunggren Ö,
- Kullberg J,
- et al
- ↵
- ↵
- ↵
- ↵
- US Food and Drug Administration (FDA)
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵Drug Topics. FDA approves label changes to SGLT2 inhibitors. https://www.drugtopics.com/view/fda-approves-safety-labeling-changes-sglt2-inhibitors. Accessed November 2, 2020.
- ↵
- Garber AJ,
- Handelsman Y,
- Grunberger G,
- et al
- ↵
- Dandona P,
- Mathieu C,
- Phillip M,
- et al
- ↵
- Rosenstock J,
- Marquard J,
- Laffel LM,
- et al
- ↵
- Henry RR,
- Thakkar P,
- Tong C,
- Polidori D,
- Alba M
- ↵
Log in using your username and password
Registration is Now Required for Free Access to CCJM Content
Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.
If you are using a mobile device, click on the settings icon to access the Register link.
In this issue
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 1
1 Jan 2021
The role of SGLT-2 inhibitors in managing type 2 diabetes
Yumiko Tsushima, M. Cecilia Lansang, Vinni Makin
Cleveland Clinic Journal of Medicine Jan 2021, 88 (1) 47-58; DOI: 10.3949/ccjm.88a.20088
Jump to section
- Article
- ABSTRACT
- SODIUM-GLUCOSE COTRANSPORTER-2
- EFFECT ON GLYCEMIC CONTROL
- EFFECT ON CARDIOVASCULAR OUTCOMES
- POSSIBLE MECHANISMS OF CARDIOVASCULAR BENEFIT
- EFFECT ON RENAL OUTCOMES
- MECHANISM OF RENAL PROTECTION
- EFFECT ON METABOLIC OUTCOMES
- STUDIES IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
- ADVERSE EFFECTS OF SGLT-2 INHIBITORS
- REVIEW OF THE GUIDELINES
- FUTURE DIRECTIONS
- DISCLOSURES
- REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
- No related articles found.